02252 PE Ratio & Valuation,Is 02252 Overvalued — Intellectia
02252 Relative Valuation
02252's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, 02252 is overvalued; if below, it's undervalued.
Historical Valuation
MEDBOT-B(02252) is now in theFairzone, suggesting that its currentforward PSratio of24.45is consideredFairlycompared with the five-year average of-39.92.The fair price ofMEDBOT-B(02252)is between14.09to23.26according to relative valuation methord.
Relative Value
Fair Zone
14.09-23.26
Current Price：19.86
Fair
-113.27
PE
1Y
3Y
5Y
Trailing
Forward
1021.77
EV/EBITDA
MEDBOT-B. (02252) has a current EV/EBITDA of 1021.77. The 5-year average EV/EBITDA is -1.08. The thresholds are as follows: Strongly Undervalued below -558.87, Undervalued between -558.87 and -279.98, Fairly Valued between 277.81 and -279.98, Overvalued between 277.81 and 556.71, and Strongly Overvalued above 556.71. The current Forward EV/EBITDA of 1021.77 falls within the Strongly Overvalued range.
-238.36
EV/EBIT
MEDBOT-B. (02252) has a current EV/EBIT of -238.36. The 5-year average EV/EBIT is -47.05. The thresholds are as follows: Strongly Undervalued below -164.42, Undervalued between -164.42 and -105.73, Fairly Valued between 11.64 and -105.73, Overvalued between 11.64 and 70.33, and Strongly Overvalued above 70.33. The current Forward EV/EBIT of -238.36 falls within the Strongly Undervalued range.
24.45
PS
MEDBOT-B. (02252) has a current PS of 24.45. The 5-year average PS is 170.56. The thresholds are as follows: Strongly Undervalued below -421.62, Undervalued between -421.62 and -125.53, Fairly Valued between 466.65 and -125.53, Overvalued between 466.65 and 762.75, and Strongly Overvalued above 762.75. The current Forward PS of 24.45 falls within the Historic Trend Line -Fairly Valued range.
-224.12
P/OCF
MEDBOT-B. (02252) has a current P/OCF of -224.12. The 5-year average P/OCF is -50.85. The thresholds are as follows: Strongly Undervalued below -144.75, Undervalued between -144.75 and -97.80, Fairly Valued between -3.90 and -97.80, Overvalued between -3.90 and 43.06, and Strongly Overvalued above 43.06. The current Forward P/OCF of -224.12 falls within the Strongly Undervalued range.
-153.91
P/FCF
MEDBOT-B. (02252) has a current P/FCF of -153.91. The 5-year average P/FCF is -40.39. The thresholds are as follows: Strongly Undervalued below -103.87, Undervalued between -103.87 and -72.13, Fairly Valued between -8.66 and -72.13, Overvalued between -8.66 and 23.08, and Strongly Overvalued above 23.08. The current Forward P/FCF of -153.91 falls within the Strongly Undervalued range.
MEDBOT-B (02252) has a current Price-to-Book (P/B) ratio of 34.97. Compared to its 3-year average P/B ratio of 34.61 , the current P/B ratio is approximately 1.06% higher. Relative to its 5-year average P/B ratio of 28.98, the current P/B ratio is about 20.67% higher. MEDBOT-B (02252) has a Forward Free Cash Flow (FCF) yield of approximately -1.22%. Compared to its 3-year average FCF yield of -4.23%, the current FCF yield is approximately -71.23% lower. Relative to its 5-year average FCF yield of -3.85% , the current FCF yield is about -68.40% lower.
34.97
P/B
Median3y
34.61
Median5y
28.98
-1.22
FCF Yield
Median3y
-4.23
Median5y
-3.85
Performance Decomposition
1Y
3Y
5Y
Market capitalization of 02252 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 02252 in the past 1 year is driven by Unknown.
Is MEDBOT-B (02252) currently overvalued or undervalued?
MEDBOT-B(02252)is now in theFairzone, suggesting that its currentforward PSratio of 24.45is consideredFairlycompared with the five-year average of-39.92.The fair price of MEDBOT-B(02252)is between14.09to23.26according to relative valuation methord.
What is MEDBOT-B (02252) fair value?
02252's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of MEDBOT-B (02252) is between 14.09to23.26 according to relative valuation methord.
How does 02252's valuation metrics compare to the industry average?
The average P/S ratio for 02252's competitors is , providing a benchmark for relative valuation. MEDBOT-B Corp (02252) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for MEDBOT-B (02252) as of Dec 17 2025?
As of Dec 17 2025, MEDBOT-B (02252) has a P/B ratio of 34.97. This indicates that the market values 02252 at 34.97 times its book value.
What is the current FCF Yield for MEDBOT-B (02252) as of Dec 17 2025?
As of Dec 17 2025, MEDBOT-B (02252) has a FCF Yield of -1.22%. This means that for every dollar of MEDBOT-B’s market capitalization, the company generates -1.22 cents in free cash flow.
What is the current Forward P/E ratio for MEDBOT-B (02252) as of Dec 17 2025?
As of Dec 17 2025, MEDBOT-B (02252) has a Forward P/E ratio of -113.27. This means the market is willing to pay $-113.27 for every dollar of MEDBOT-B’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for MEDBOT-B (02252) as of Dec 17 2025?
As of Dec 17 2025, MEDBOT-B (02252) has a Forward P/S ratio of 24.45. This means the market is valuing 02252 at $24.45 for every dollar of expected revenue over the next 12 months.
